The third day of testimony begins Wednesday morning as prosecutors continue building their case against Ibraheem Yazeed in ...

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

CSL’s new Illinois investment adds to over $3B spent on U.S. operations since 2018. The expansion will create at least 300 ...

Article Summary Australian biotechnology company to invest $1.5 billion by 2031 to expand Kankakee plasma-processing facility. The expansion will create ...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018Expansion will create at least 300 new jobs and ...

Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...